David J M Barnett
Overview
Explore the profile of David J M Barnett including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
26
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hillege L, Barnett D, Ziemons J, Aarnoutse R, de Vos-Geelen J, van Geel R, et al.
Sci Rep
. 2025 Mar;
15(1):7874.
PMID: 40050324
Tamoxifen is essential in treating estrogen receptor-positive (ER+) breast cancer, primarily through its active metabolite, endoxifen. Emerging research suggests potential interactions between tamoxifen and gut microbiota. This study investigates the...
2.
Endika M, Barnett D, Klostermann C, Kok N, Schols H, Nauta A, et al.
Gut Microbiome (Camb)
. 2025 Jan;
5():e7.
PMID: 39776540
Breastfeeding represents a strong selective factor for shaping the infant gut microbiota. Besides providing nutritional requirements for the infant, human milk is a key source of oligosaccharides, human milk oligosaccharides...
3.
Ziemons J, Hillege L, Aarnoutse R, de Vos-Geelen J, Valkenburg-van Iersel L, Mastenbroek J, et al.
BMC Microbiol
. 2024 Jun;
24(1):222.
PMID: 38918717
Background: 5-Fluorouracil (5-FU) is used as an antineoplastic agent in distinct cancer types. Increasing evidence suggests that the gut microbiota might modulate 5-FU efficacy and toxicity, potentially affecting the patient's...
4.
Endika M, Barnett D, Klostermann C, Schols H, Arts I, Penders J, et al.
Front Microbiol
. 2023 Jun;
14:1131953.
PMID: 37275167
Antibiotic exposure disturbs the developing infant gut microbiota. The capacity of the gut microbiota to recover from this disturbance (resilience) depends on the type of antibiotic. In this study, infant...
5.
The Role of Intestinal Microbiota in Metastatic Colorectal Cancer Patients Treated With Capecitabine
Aarnoutse R, Ziemons J, de Vos-Geelen J, Valkenburg-van Iersel L, Wildeboer A, Vievermans A, et al.
Clin Colorectal Cancer
. 2021 Nov;
21(2):e87-e97.
PMID: 34801414
Background: Previous pre-clinical research has indicated that the intestinal microbiota can potentiate anti-tumour efficacy of capecitabine and that capecitabine treatment impacts intestinal microbiota composition and diversity. Using a longitudinal design,...
6.
Barnett D, Mommers M, Penders J, Arts I, Thijs C
J Allergy Clin Immunol
. 2019 Feb;
143(6):2305-2307.
PMID: 30796982
No abstract available.